655 related articles for article (PubMed ID: 26882049)
1. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
[TBL] [Abstract][Full Text] [Related]
2. The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy.
Carnovale C; Brusadelli T; Zuccotti G; Beretta S; Sullo MG; Capuano A; Rossi F; Moschini M; Mugelli A; Vannacci A; Laterza M; Clementi E; Radice S;
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S1-8. PubMed ID: 25171154
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
5. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system.
Monteiro C; Duarte AP; Alves G
Expert Opin Drug Saf; 2021 Jan; 20(1):109-118. PubMed ID: 33170742
[No Abstract] [Full Text] [Related]
7. FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
Fracchiolla NS; Artuso S; Cortelezzi A; Pelizzari AM; Tozzi P; Bonfichi M; Bocchio F; Gargantini L; De Rosa E; Vighi GD; Prestini L; Sammassimo S; Frungillo N; Pasquini MC; Ragazzi A; Boghi D; Pastore A; Lanzi E; Gritti G; Quaresmini G; Voltolini S; Gaiardoni R; Corti C; Vilardo MC; La Targia ML; Berini G; Magagnoli M; Bacci C; Consonni D; Rivolta AL; Muti G
Hematol Oncol; 2018 Feb; 36(1):299-306. PubMed ID: 28771763
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
[TBL] [Abstract][Full Text] [Related]
9. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
12. Understanding adverse drug reactions in older adults through drug-drug interactions.
Marengoni A; Pasina L; Concoreggi C; Martini G; Brognoli F; Nobili A; Onder G; Bettoni D
Eur J Intern Med; 2014 Nov; 25(9):843-6. PubMed ID: 25312593
[TBL] [Abstract][Full Text] [Related]
13. A retrospective review of paediatric adverse drug reactions reported in Lombardy and Croatia from 2005 to 2013.
Carnovale C; Gentili M; Matacena M; Dimov Di Giusti M; Krnic D; Dolinic B; Kolaric D; Margan Koletic Z; Macolic Sarinic V; Culjak M; Fortino I; Merlino L; Clementi E; Radice S
Expert Opin Drug Saf; 2016 Dec; 15(sup2):35-43. PubMed ID: 27875921
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.
Aagaard L; Weber CB; Hansen EH
Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864
[TBL] [Abstract][Full Text] [Related]
15. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
Aldea A; García Sánchez-Colomer M; Fernández Quintana E; García Sáiz M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1329-38. PubMed ID: 22415248
[TBL] [Abstract][Full Text] [Related]
16. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.
Leone R; Magro L; Moretti U; Cutroneo P; Moschini M; Motola D; Tuccori M; Conforti A
Drug Saf; 2010 Aug; 33(8):667-75. PubMed ID: 20635825
[TBL] [Abstract][Full Text] [Related]
17. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
[TBL] [Abstract][Full Text] [Related]
18. Pediatric pharmacovigilance in an institute of national importance: Journey has just begun.
Sharma PK; Misra AK; Gupta N; Khera D; Gupta A; Khera P
Indian J Pharmacol; 2017; 49(5):390-395. PubMed ID: 29515280
[TBL] [Abstract][Full Text] [Related]
19. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study.
Lombardi N; Crescioli G; Bettiol A; Marconi E; Vitiello A; Bonaiuti R; Calvani AM; Masi S; Lucenteforte E; Mugelli A; Giovannelli L; Vannacci A
BMC Pharmacol Toxicol; 2018 Apr; 19(1):16. PubMed ID: 29661234
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
